Five Questions With: Pam Stetkiewicz

After operating in stealth for its first year, Lyora Therapeutics publicly launched in July, announcing Pam Stetkiewicz as the Providence-based biotech company’s CEO. With $2.5 million in pre-seed funding, Lyora develops medications for those living with inherited retinal diseases that currently have no treatment options. The firm is currently developing medications for vision loss and potential blindness caused by retinitis pigmentosa, Usher syndrome and Leber’s congenital amaurosis. PBN: You&...